Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$42.18 USD

42.18
890,330

+1.07 (2.60%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $42.20 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

NEOGEN's (NEOG) New Test to Identify Coronavirus in Wastewater

by Zacks Equity Research

Launch of NEOGEN's (NEOG) latest test, which marks its entry into wastewater testing, is expected to become a key tool to combat COVID-19.

QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Improve

by Zacks Equity Research

QIAGEN's (QGEN) high level of sales for product groups used in the COVID-19 pandemic response drove the top line.

Qiagen (QGEN) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 3.03% and 3.51%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

QIAGEN (QGEN) Announces COVID-19 Test Updates as Cases Rise

by Zacks Equity Research

QIAGEN (QGEN) along with with Australia-based digital diagnostics company, Ellume develops QIAreach SARS-CoV-2 Antigen Test.

The Zacks Analyst Blog Highlights: Abbott Lab, QIAGEN, Quidel, Hologic and Quest Diagnostics

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott Lab, QIAGEN, Quidel, Hologic and Quest Diagnostics

Urmimala Biswas headshot

Testing Space in Focus Again Thanks to New Wave of Coronavirus

by Urmimala Biswas

The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.

Trina Mukherjee headshot

3 Soaring MedTech Stocks That Might Lose Ground in 2021

by Trina Mukherjee

Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Bruker (BRKR) Launches PCR Panel, Expands Testing Portfolio

by Zacks Equity Research

Bruker's (BRKR) winter four-plex panel is expected to facilitate diagnosis and patient management by facilitating the use of saliva samples as well.

Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

    Trina Mukherjee headshot

    4 Top-Ranked MedTech Stocks to Bet on Heading Into 2021

    by Trina Mukherjee

    Grab these four top stocks that have shown tremendous promise despite market volatility due to the pandemic and have the potential to continue their bull run in 2021.

    QIAGEN (QGEN) Launches RUO Solution to Explore Immune Response

    by Zacks Equity Research

    QIAGEN's (QGEN) latest RUO solution is expected to provide better insights into the course of the COVID-19 infection and aid in vaccine development and deployment.

    Is QIAGEN (QGEN) a Profitable Stock to Pick Right Now ?

    by Zacks Equity Research

    Is QIAGEN (QGEN) a great pick from the value investor's perspective right now? Read on to know more.

    QIAGEN (QGEN), BioNTech to Develop Test to Identify SCCHN

    by Zacks Equity Research

    QIAGEN (QGEN) aims to leverage its global reach and position in CDx and HPV testing by collaborating with BioNTech.

    Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now

    by Zacks Equity Research

    Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

    QIAGEN (QGEN) Launches PCR Test, Expands Testing Portfolio

    by Zacks Equity Research

    QIAGEN (QGEN) aims to expand its NeuMoDx testing menu with the latest test launch and label extension.

    QIAGEN (QGEN) Launches COVID-19 Antigen Test With Ellume

    by Zacks Equity Research

    QIAGEN (QGEN) starts commercializing latest test after filing for FDA emergency use authorization (EUA) for symptomatic patients.

    Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?

    by Zacks Equity Research

    Sector ETF report for PBE

    Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?

    by Zacks Equity Research

    Sector ETF report for PBE

    QIAGEN (QGEN) Q3 Earnings Beat Estimates, FY20 Guidance Up

    by Zacks Equity Research

    QIAGEN (QGEN) registeres robust revenue growth across geographies and both operating segments in Q3 despite the coronavirus-led economic crisis.

    Qiagen (QGEN) Tops Q3 Earnings and Revenue Estimates

    by Zacks Equity Research

    Qiagen (QGEN) delivered earnings and revenue surprises of 5.46% and 7.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

    Align's (ALGN) ClinCheck Suite Now Commercially Available

    by Zacks Equity Research

    Align Technology's (ALGN) ClinCheck treatment-planning software's commercial availability is expected to boost doctor performances due to ready availability of treatment plans.

    Intersect ENT (XENT) Posts Preliminary Q3 Data, Dull Q4 View

    by Zacks Equity Research

    Intersect ENT (XENT) expects the strength in its product lines to have substantially boosted revenues in the third quarter.

    The Zacks Analyst Blog Highlights: Edwards Lifesciences, QIAGEN, IDEXX, LHC and ResMed

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Edwards Lifesciences, QIAGEN, IDEXX, LHC and ResMed